Boston Scientific's Restructuring: A Cost-Cutting Gambit Amidst Deeper MedTech Headwinds

Related Articles

Boston Scientific Insiders Bet on a Long-Term Rebound Amidst Near-Term Headwinds

1 months ago

Why is Boston Scientific Acquiring Penumbra

6 months ago

What's Brewing for Boston Beer's Q4 Earnings

7 months ago

What Does Paloma Partners' Divestment Mean for Core Scientific

6 months ago

Category

You may also like

Stock News•1 week ago

Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?

Boston Scientific's ICVT sales rose 15% as coronary therapies gained traction. New devices and deals could extend growth momentum, though sustainability depends on continued adoption and execution.

ICVT

Share

Stock News•1 months ago

Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?

Boston Scientific's valuation is cheaper, offering upside, but weaker guidance, share losses, higher debt, and delayed catalysts suggest caution. Investors may wait for clearer signals before acting.

BSX

Share

Stock News•1 months ago

Boston Scientific unveils new restructuring plan, expects job cuts

Boston Scientific announced a new company-wide restructuring plan approved by its board, expecting job cuts to reduce costs and position for future growth, per a Monday regulatory filing.

BSX

Share